Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Cinven’s portfolio company Partner in Pet Food in connection with its acquisition of the Doggy
Mandate

Vinge advises Cinven’s portfolio company Partner in Pet Food in connection with its acquisition of the Doggy

July 08, 2020 EU, Competition and Regulatory Employment and Benefits IT, Telecommunications and Outsourcing Banking and Finance M&A Corporate Commercial

Vinge advises Cinven’s portfolio company Partner in Pet Food, a leading European pet food manufacturer, in connection with its acquisition of the Doggy Group (“Doggy”).

Doggy is a leading Swedish pet food producer and distribution with well-known brands such as Doggy, Mjau and Bozita. The acquisition will complement Partner in Pet Food's product range, geographical markets and distribution channels.

The transaction is conditional upon customary approvals by competition authorities.

Vinge’s team mainly consisted of partner Christina Kokko and associates Carl Sander, Hannah Kajlinger and Jonathan Riddersholm (M&A), Christoffer Nordin and Ellinor Wargenbrant (Corporate Commercial), Olof Löfvenberg (Environment & Permits), Axel Jansson and Felix Möller (Banking & Finance), Lisa Ullman and Ebba Svenburg (Employment), Karl-Hugo Engdahl (IT), Xandra Ståhlberg and Lisa Malmborg (Antitrust) and VDR-assistant Carl Bruneheim.

 

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026